Table 1.

Recommended 1st and 2nd line antiretroviral therapy (ART) regimens for children and youth in Kenya [33,34].

Age and weight	Recommended 1st line ART at study start	Updated 1st line ART during study implementation	Recommended 2nd line ART
Birth-4 weeks	AZT + 3 TC + RAL or NVP	AZT + 3 TC + RAL or NVP	ABC + 3 TC + LPV/r
>4 weeks and <3 years, <20 kg	AZT (or ABC) + 3 TC + LPV/r	ABC + 3 TC + LPV/r	DRM testing-guided 2nd line
≥3 years and 20–35 kg	ABC (or AZT) + 3 TC + EFV (or RAL) ABC (or AZT) + 3 TC + LPV/r	ABC + 3 TC + DTG	ABC (or AZT) + 3 TC + LPV/r DRM testing-guided 2nd line
≥15 years or >35 kg	TDF (or ABC) + 3 TC + DTG (or EFV)	TDF + 3 TC + DTG	AZT (or TDF) + 3 TC + ATV/r

ART = antiretroviral therapy; AZT = zidovidine; 3 TC = lamivudine; RAL = raltegravir; NVP = nevirapine; ABC = abacavir; LPV/r = lopinavir/boosted ritonavir; EFV = efavirenz; TDF = tenofovir; DTG = dolutegravir; DRM = drug resistance mutation; ATV/r = atazanavir/boosted ritonavir.